Mandate

Vinge advised Active Biotech on its rights offering

December 10, 2020 Capital Markets and Public M&A

Vinge advised Active Biotech AB (publ) in connection with its rights offering.

Related

Vinge advises Borgo in connection with its inaugural issuance of primary capital instruments (AT1)

Vinge has advised Borgo AB (publ) in connection with its successful issuance of primary capital instruments (so called “AT1 bonds”) in the amount of SEK 350 million with a floating rate coupon of 3-month STIBOR + 390 basis points.
January 29, 2026

Vinge advises Pyrotek Global Holdings in conjunction with acquisition

Vinge has advised Pyrotek Global Holdings Inc. in conjunction with its acquisition of SFX controllers Sweden AB, Unique Pyrotechnic ApS, Unique Pyrotechnic AS, Laserteknikk AS, Fyrverkeri Experterna Per Hultgren AB and Unique Pyrotechnic AB.
January 29, 2026

Vinge advises J Bil in conjunction with the acquisition of Appelskog Bil AB

Vinge has advised the buyer J Bil AB in conjunction with the acquisition of all shares in Appelskog Bil AB.
January 29, 2026